These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28988723)

  • 21. A Small Change Can Make a Big Difference: A Lesson from Evolocumab.
    Mirzaee S; Thein PM; Wong D; Nasis A
    Heart Lung Circ; 2019 Mar; 28(3):e21-e22. PubMed ID: 29685715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity?
    Gasparovic J; Basistová Z; Fábryová L; Wsólová L; Vohnout B; Raslová K;
    Atherosclerosis; 2007 Oct; 194(2):e95-107. PubMed ID: 17194460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Bajaj A; Cuchel M
    Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.
    Di Taranto MD; Benito-Vicente A; Giacobbe C; Uribe KB; Rubba P; Etxebarria A; Guardamagna O; Gentile M; Martín C; Fortunato G
    Sci Rep; 2017 Nov; 7(1):15282. PubMed ID: 29127338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines.
    Jones LK; Jefferson CR; Chen N; Murray MF
    Coron Artery Dis; 2021 Sep; 32(6):588-589. PubMed ID: 33394692
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Bea AM; Perez-Calahorra S; Marco-Benedi V; Lamiquiz-Moneo I; Jarauta E; Mateo-Gallego R; Civeira F
    Atherosclerosis; 2017 Aug; 263():92-96. PubMed ID: 28623742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia.
    Li B; Hao PP; Zhang Y; Yin RH; Kong QZ; Cai XJ; Zhao Z; Qi JN; Li Y; Xiao J; Wang F; Yi W; Ji XP; Su GH
    Oncotarget; 2017 May; 8(18):30455-30463. PubMed ID: 27458166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
    Reeskamp LF; Millar JS; Wu L; Jansen H; van Harskamp D; Schierbeek H; Gipe DA; Rader DJ; Dallinga-Thie GM; Hovingh GK; Cuchel M
    Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1753-1759. PubMed ID: 33691480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.
    Hopkins PN; Defesche J; Fouchier SW; Bruckert E; Luc G; Cariou B; Sjouke B; Leren TP; Harada-Shiba M; Mabuchi H; Rabès JP; Carrié A; van Heyningen C; Carreau V; Farnier M; Teoh YP; Bourbon M; Kawashiri MA; Nohara A; Soran H; Marais AD; Tada H; Abifadel M; Boileau C; Chanu B; Katsuda S; Kishimoto I; Lambert G; Makino H; Miyamoto Y; Pichelin M; Yagi K; Yamagishi M; Zair Y; Mellis S; Yancopoulos GD; Stahl N; Mendoza J; Du Y; Hamon S; Krempf M; Swergold GD
    Circ Cardiovasc Genet; 2015 Dec; 8(6):823-31. PubMed ID: 26374825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
    Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
    Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?
    Page MM; Bell DA; Watts GF
    Clin Genet; 2020 Apr; 97(4):543-555. PubMed ID: 31833051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.